Abstract: The invention relates to immunogenic peptides derived from Myelin Oligodendrocyte Glycoprotein (MOG) for use in the treatment of demyelinating disorders and to the generation of cytolytic CD4+ T cells or NKT cells against antigen presenting cells that present the wild-type MOG epitope sequence.

Abstract: The present invention relates to a pharmaceutical preparation (combination or pharmaceutical composition or kit-of-parts) comprising one or more dose units of a fumarate compound and an immunogenic or tolerogenic peptide comprising an oxidoreductase motif and an NKT cell epitope or an MHC class II T cell epitope of an (auto)antigen involved in fumarate related diseases or disorders. The present invention further relates to medical uses of this pharmaceutical preparation.

Abstract: This invention relates to novel methods for producing recombinant allergens, including but not limited to proDer p 1, the precursor form of the major protein allergen from Dermatophagoides pteronyssinus Der p 1, and to recombinant allergens produced by such methods. The invention further relates to the use of said recombinant allergens in formulating immunogenic compositions and vaccines effective in the prevention and/or the reduction of allergic responses to specific allergens.